Senores Pharmaceuticals IPO allotment: How to check status online on Link Intime India, NSE, BSE

2 min read | Updated on December 26, 2024, 08:03 IST

SUMMARY

Senores Pharmaceuticals IPO allotment: Investors who placed bids for Senores Pharmaceuticals IPO can check the finalisation details on the NSE, the BSE and registrar Link Intime India websites.

Senores Pharmaceuticals IPO is a fresh issue valued at ₹500 crore and an ₹82.11 crore worth offer-for-sale.

Senores Pharmaceuticals IPO allotment: Following a robust investor response, Senores Pharmaceuticals Ltd's allotment status will likely be finalised on Thursday, December 26.

The ₹582.11-crore initial share sale was subscribed 93.69 times as it got bids for 79.95 crore shares against 85.34 lakh shares on offer.

Non-institutional investors quota fetched 96.30 times the subscription, while the qualified institutional buyers (QIBs) category attracted 94.66 times the subscription. The part meant for retail investors mopped up 90.46 times the subscription.

Investors who placed bids for Senores Pharmaceuticals IPO can check the finalisation details on the NSE, the BSE and registrar Link Intime India websites.

Senores Pharmaceuticals IPO allotment status: How to check allotment status on NSE

First, visit NSE's IPO finalisation verification page HERE.
Registered users can log in. If you are a new user, please register
Pick 'Senores Pharmaceuticals Ltd' from the dropdown list
Fill in the application number and PAN
Click on the 'Submit'

Senores Pharmaceuticals IPO allotment status can also be checked on the BSE website.

How to check Senores Pharmaceuticals IPO allotment status on Link Intime

Head of Link Intime India - https://linkintime.co.in/initial_offer/public-issues.html
Pick 'Senores Pharmaceuticals Ltd'
Enter details like application number, PAN, DP ID or account number
Click on the 'Submit'.

Senores Pharmaceuticals IPO listing date and time

Shares of Senores Pharmaceuticals will make their market debut on Monday, December 30 at 10 am.

Before the IPO, the company had raised around ₹261 crore in the anchor round.

The IPO price band was set at ₹372-₹391 a unit.

Senores Pharmaceuticals IPO is a fresh issue valued at ₹500 crore and an ₹82.11 crore worth offer-for-sale.

Funds generated will be used to set up a manufacturing facility, fund the working capital needs of the company and its subsidiaries, back inorganic growth, clear debt and general corporate purposes.

Senores Pharmaceuticals develops generic pharmaceutical products and has products in major therapeutic segments, including antibacterial, antifungal, antibiotics and bloodlines.

Senores Pharmaceuticals financials

Particulars	FY22	FY23	FY24	Q1FY25
Revenue	₹14.17 cr	₹35.34 cr	₹214.52 cr	₹181.02 cr
Net Profit	₹0.99 cr	₹8.44 cr	₹32.71 cr	₹23.94 cr

To learn more about IPO listings, schedules, and upcoming IPOs, visit our page.

About The Author

Upstox News Desk is a team of journalists who passionately cover stock markets, economy, commodities, latest business trends, and personal finance.

Upstox Securities Pvt. Ltd.: SEBI Registration No. INZ000315837 | NSE TM Code: 13942 | BSE TM Code: 6155 | CDSL Reg No.: IN-DP-761-2024 | CIN: U65100DL2021PTC376860 | Compliance Officer: Mr. Kapil Jaikalyani. Tel No.: (022) 24229920. Email ID: compliance@upstox.com | Registered Address: 809, New Delhi House, Barakhamba Road, Connaught Place, New Delhi - 110001 | RKSV Commodities India Pvt. Ltd.: SEBI Registration No.: INZ000015837 | MCX TM Code: 46510 | CIN: U74900DL2009PTC189166 | Compliance Officer: Mr. Amit Lalan. Tel No.: (022) 24229920. Email ID: compliance@rksv.in | Registered Address: 807, New Delhi House, Barakhamba Road, Connaught Place, New Delhi - 110001. Correspondence Address: 30th Floor, Sunshine Tower, Senapati Bapat Marg, Dadar (West), Mumbai - 400013. | For any complaints, email at complaints@upstox.com and complaints.mcx@upstox.com.

Procedure to file a complaint on SEBI SCORES: Register on the SCORES portal. Mandatory details for filing complaints on SCORES include: Name, PAN, Address, Mobile Number, and E-mail ID. Benefits include effective communication and speedy redressal of grievances. Please ensure you carefully read the Risk Disclosure Document as prescribed by SEBI, along with our Terms of Use and Privacy Policy.

Upstox Securities Private Limited is a wholly owned subsidiary of RKSV Securities India Private Limited and RKSV Commodities India Private Limited is an associate of RKSV Securities India Private Limited.

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing.
*Brokerage will not exceed the SEBI prescribed limit.

Risk disclosures on derivatives -

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Mutual Funds: Top rated funds do not constitute any advice. Research data is powered by Morningstar. Please read the offer documents carefully before investing. Upstox shall not accept any liability arising out of your investments.
These are not Exchange traded products, and the Member is just acting as distributor. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism.

Attention Investors: As per NSE circular dated July 6, 2022, BSE circular dated July 6, 2022, MCX circular dated July 11, 2022 investors are cautioned to abstain them from dealing in any schemes of unauthorised collective investments/portfolio management, indicative/ guaranteed/fixed returns / payments etc. Investors are further cautioned to avoid practices like:
a) Sharing i) trading credentials – login id & passwords including OTP’s., ii) trading strategies, iii) position details.
b) Trading in leveraged products /derivatives like Options without proper understanding, which could lead to losses.
c) Writing/ selling options or trading in option strategies based on tips, without basic knowledge & understanding of the product and its risks
d) Dealing in unsolicited tips through like Whatsapp, Telegram, Instagram, YouTube, Facebook, SMS, calls, etc.
e) Trading / Trading in “Options” based on recommendations from unauthorised / unregistered investment advisors and influencers.

Kindly, read the Advisory Guidelines For Investors as prescribed by the Exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client’s assets : Advisory Guidelines For Investors

Kindly, read the advisory as prescribed by the Exchange with reference to their circular dated January 14, 2022 regarding Updation of mandatory KYC fields by March 31, 2022: KYC Updation

Attention Investors: Prevent unauthorised transactions in your Demat account by updating your mobile number with your depository participant. Receive alerts on your registered mobile number for debit and other important transactions in your Demat account directly from CDSL on the same day. Prevent unauthorised transactions in your Trading account by updating your mobile numbers/email addresses with your stock brokers. Receive information on your transactions directly from the Exchange on your mobile/email at the end of the day. Issued in the interest of investors. KYC is a one-time exercise while dealing in securities markets - once KYC is done through a SEBI-registered intermediary (broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. As a business, we don’t give stock tips and have not authorised anyone to trade on behalf of others. If you find anyone claiming to be part of Upstox or RKSV and offering such services, please send us an email at complaints@upstox.com and complaints.mcx@upstox.com.

No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor’s account. Stockbrokers can accept securities as margin from their clients only by way of a pledge in the depository system w.e.f. 1st September 2020.
Update your email ID and mobile number with your stockbroker/depository participant and receive an OTP directly from the depository on your registered email ID and/or mobile number to create a pledge.
Check your securities/mutual funds/bonds in the Consolidated Account Statement (CAS) issued by NSDL/CDSL every month.

Attention Investors: SEBI has established an Online Dispute Resolution Portal (ODR Portal) for resolving disputes in the Indian Securities Market. This circular streamlines the existing dispute resolution mechanism, offering online conciliation and arbitration, benefiting investors and listed companies. https://www.sebi.gov.in/legal/circulars/jul-2023/online-resolution-of-disputes-in-the-indian-securities-market_74794.html ODR portal for Investors - https://smartodr.in/login

Senores Pharmaceuticals IPO allotment: How to check status online on Link Intime India, NSE, BSE

Senores Pharmaceuticals IPO allotment status: How to check allotment status on NSE

How to check Senores Pharmaceuticals IPO allotment status on Link Intime

Senores Pharmaceuticals IPO listing date and time

Senores Pharmaceuticals financials

Market Wrap, December 27: SENSEX, NIFTY50 gain 1% this week; auto, healthcare stocks rally

Mamata Machinery IPO Share Price: Stock hits 5% upper circuit after listing at 146.91% premium

Indian auto sector in 2025: Growth opportunities and challenges to watch

Gold and silver price on Dec 27: Gold rate rise for third straight day amid geopolitical concerns

Trade setup: Breakout signal on NIFTY?

Trade setup: #NIFTY ends red - What lies ahead?